HomeMarket NewsMicro Cap StocksWhy Cardiff Oncology Stock Is Rising After Hours

Why Cardiff Oncology Stock Is Rising After Hours

Actionable Trade Ideas

always free

medications 257336 12803

Cardiff Oncology (CRDF) Shares Surge After-Hours

Cardiff Oncology, Inc. (CRDF) shares are experiencing a significant boost during after-hours trading on Tuesday following the company’s announcement of positive clinical data in pancreatic cancer and small cell lung cancer. The data includes promising results from the use of onvansertib monotherapy.

The Details

In an update released on Tuesday, Cardiff Oncology shared favorable clinical data from ongoing trials involving onvansertib monotherapy and combination therapy for metastatic pancreatic ductal adenocarcinoma and small cell lung cancer. Additionally, the company revealed plans for a first-line investigator-initiated trial combining onvansertib with standard-of-care treatment for pancreatic cancer.

Cardiff Oncology’s CEO, Mark Erlander, expressed excitement about the data, stating, β€œWe are thrilled that these trials, targeting two difficult-to-treat cancers with low survival rates, have provided encouraging results. This expands the potential application of onvansertib beyond our main program in RAS-mutated mCRC.”

He further added, β€œThe strength of the data in pancreatic cancer supports the rationale for conducting a first-line trial using onvansertib in combination with standard-of-care treatment, which we believe will greatly benefit patients. In the case of small cell lung cancer, we are encouraged by the observed single-agent activity of onvansertib monotherapy in this challenging extensive stage refractory setting.”

Rising Stock Prices

The positive news from Cardiff Oncology has had a significant impact on the company’s stock. As of the publication time, CRDF shares were up 6.7% in after-hours trading, reaching $1.73 per share according to Benzinga Pro.

Conclusion

Cardiff Oncology’s release of positive clinical data in pancreatic cancer and small cell lung cancer has led to a surge in stock prices. Investors are optimistic about the potential of onvansertib monotherapy and the planned trials with standard-of-care treatment. As the company continues to make progress in its research and development efforts, the future looks promising for Cardiff Oncology and its shareholders.

Related Link: Why MillerKnoll Stock Surged After Hours

Image by Michal Jarmoluk from Pixabay

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.